AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+21.03%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$261M
AUM Growth
–
Cap. Flow
+$261M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
85.68%
Holding
24
New
24
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Novo Nordisk
NVO
|
$50.2M |
| 2 |
Eli Lilly
LLY
|
$38.2M |
| 3 |
argenx
ARGX
|
$32.3M |
| 4 |
Merck
MRK
|
$29.3M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$19.5M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Novo Nordisk
NVO
$251B
| $50.2M | 19.14% |
+371,055
| New | +$50.2M |
|
|
2
Eli Lilly
LLY
$657B
| $38.2M | 14.55% |
+104,328
| New | +$38.2M |
|
|
3
argenx
ARGX
$43.6B
| $32.3M | 12.3% |
+85,204
| New | +$32.3M |
|
|
4
Merck
MRK
$210B
| $29.3M | 11.17% |
+264,200
| New | +$29.3M |
|
|
KRTX
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $19.5M | 7.43% |
+99,267
| New | +$19.5M |
|
6
AbbVie
ABBV
$372B
| $14.7M | 5.59% |
+90,821
| New | +$14.7M |
|
7
Moderna
MRNA
$9.37B
| $13.4M | 5.11% |
+74,719
| New | +$13.4M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.8M | 4.12% |
+504,615
| New | +$10.8M |
|
9
Biogen
BIIB
$19.4B
| $8.31M | 3.17% |
+30,000
| New | +$8.31M |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.58M | 2.51% |
+51,175
| New | +$6.58M |
|
11
BioNTech
BNTX
$24B
| $5.57M | 2.12% |
+37,108
| New | +$5.57M |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $5.37M | 2.05% |
+45,000
| New | +$5.37M |
|
13
AstraZeneca
AZN
$248B
| $5.27M | 2.01% |
+77,759
| New | +$5.27M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.8M | 1.45% |
+15,971
| New | +$3.8M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.92M | 1.11% |
+28,217
| New | +$2.92M |
|
16
Thermo Fisher Scientific
TMO
$186B
| $2.8M | 1.07% |
+5,088
| New | +$2.8M |
|
|
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $2.46M | 0.94% |
+22,321
| New | +$2.46M |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.2M | 0.84% |
+41,600
| New | +$2.2M |
|
19
Vertex Pharmaceuticals
VRTX
$100B
| $2.05M | 0.78% |
+7,114
| New | +$2.05M |
|
20
Viking Therapeutics
VKTX
$3.04B
| $1.23M | 0.47% |
+130,913
| New | +$1.23M |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $1.04M | 0.4% |
+39,951
| New | +$1.04M |
|
22
Waters Corp
WAT
$18B
| $975K | 0.37% |
+2,845
| New | +$975K |
|
23
Amylyx Pharmaceuticals
AMLX
$836M
| $882K | 0.34% |
+23,883
| New | +$882K |
|
24
Kymera Therapeutics
KYMR
$2.95B
| $749K | 0.29% |
+30,000
| New | +$749K |
|